Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Jagsonpal Pharmaceuticals is trading at Rs 224.31 with near-term consolidation expected , the 2027 target of Rs 179 is approximately 20 percent below the current price. The more compelling case is in the outer years , Rs 210 by 2028 and Rs 280 by 2030 , as the earnings model builds toward that trajectory. FY26 EPS of ₹6.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to approximately13% further out.

This article breaks down the Jagsonpal Pharmaceuticals share price target for 2027, 2028, and 2030, the sector-specific drivers behind the analyst model, and the risks that could delay or derail the forecast.

Click Here – Get Free Investment Predictions

Jagsonpal Pharmaceuticals Company Overview and Share Price Target Summary

Metric	Details
NSE Ticker	JAGSNPHARM
Sector	Pharma and Healthcare
CMP (13 Aug 2026)	Rs 224.31
Market Cap	Rs 1476 Cr
Jagsonpal Pharmaceuticals Share Price Target 2027	Rs 179 (-20%)
Jagsonpal Pharmaceuticals Share Price Target 2028	Rs 210 (-6%)
Jagsonpal Pharmaceuticals Share Price Target 2030	Rs 280 (+25%)
Bull Case 2030	Rs 358
Bear Case 2030	Rs 210

What most investors miss about Jagsonpal Pharmaceuticals: Completed acquisition of 77.21% stake in Aequitas Healthcare on July 8, 2026, a fresh inorganic growth catalyst

FY26 EPS of ₹6.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to approximately13% further out..

Why Analysts Have Set the Jagsonpal Pharmaceuticals share price target at Rs 179 for 2027

Domestic Formulations Revenue Is Growing Ahead of Sector

This is the clearest reason the analyst model converges on Rs 280 by 2030. FY26 EPS of ₹6.4 growing approximately16% a year, capitalised at approximately24x forward earnings; growth tapers to app. Tracking this factor quarterly gives the earliest signal on whether the long-term analyst target stays on course.

Export Markets and Regulatory Compliance Give Revenue Visibility

The Jagsonpal Pharmaceuticals share price target for 2028 , Rs 210 , is built partly on this continuing to hold. If it deteriorates, the timeline for the outer-year forecast extends, not the target itself. Investors should track it with every results cycle.

New Product Approvals Will Drive the Next Leg of Growth

This underpins Jagsonpal Pharmaceuticals's growth beyond the 2027 near-term. It is the kind of durable structural factor that keeps analysts positive on the 2030 target even when quarterly numbers disappoint.

Manufacturing Scale Keeps Cost Structures Competitive

For the 2028 recovery thesis to work, Jagsonpal Pharmaceuticals needs to maintain consistency here. One cycle of weakness would not break the long-term case, but two consecutive quarters of deterioration would prompt downgrades.

India's Healthcare Spending Is Compounding at Above-GDP Rates

This is the macro layer that most company-specific screens miss. It amplifies Jagsonpal Pharmaceuticals's own earnings compounding and is why analysts are more constructive on the 2030 horizon than on 2027.

Jagsonpal Pharmaceuticals Share Price Target 2027, 2028 and 2030: Year-Wise Breakdown

2027 Target: Rs 179

Rs 179 is the 2027 analyst target, implying near-term consolidation expected , the 2027 target of Rs 179 is approximately 20 percent below the current price. At this level, Jagsonpal Pharmaceuticals would be trading on forward multiples consistent with the current earnings trajectory. The 2027 milestone is essentially a staging post , confirmed only after two to three quarters of on-track delivery.

2028 Target: Rs 210

Rs 210 is where analysts see Jagsonpal Pharmaceuticals by 2028, roughly -6 percent above today's price. By FY29, the business should have moved past the near-term consolidation, and the Jagsonpal Pharmaceuticals share price target for 2028 typically re-rates faster than markets initially expect once the earnings inflection becomes visible.

2030 Target: Rs 280

The long-term case is Rs 280 by 2030 , a potential gain of approximately 25 percent from CMP Rs 224.31, which works out to a 4-year CAGR of roughly 6 percent. By FY31, Jagsonpal Pharmaceuticals should be operating at a scale and earnings quality that justifies the multiple implied by this target. Please verify all data at NSE and BSE before making any investment decision.

Bull Case and Bear Case for Jagsonpal Pharmaceuticals by 2030

Bull Case: Rs 358

The bull case lands at Rs 358 by 2030. This requires better-than-expected earnings growth alongside a re-rating of the multiple , both need to land together. Favourable macro conditions, new business wins, or a sector re-rating could drive this scenario without needing extraordinary operational delivery from the company.

Bear Case: Rs 210

The bear case is Rs 210 by 2030 , still above today's price in most scenarios, but a significantly slower path. This applies if earnings miss across FY27 to FY28, competitive pressure intensifies, or a macro slowdown compresses sector multiples before Jagsonpal Pharmaceuticals can re-rate upward.

Scenario	Target 2030	Return	Key Assumption
Bull Case	Rs 358	+60%	Above-consensus growth; multiple expansion
Base Case	Rs 280	+25%	Base-case CAGR; peer multiples hold
Bear Case	Rs 210	-6%	Earnings miss; macro pressure; multiple contraction

Key Risks to the Jagsonpal Pharmaceuticals Forecast

Regulatory Risk

A USFDA warning letter or facility import alert would delay US launches and compress the export revenue that drives the outer-year targets.

Currency Headwind

INR appreciation against USD reduces the INR value of Jagsonpal Pharmaceuticals's foreign revenue without any change in business performance.

Generic Pricing Pressure

Pricing erosion in US generic markets, especially in key molecules, can shrink EBITDA margins faster than volume growth compensates.

Pipeline Delays

Clinical or regulatory delays in new product filings push revenue ramp timelines, affecting the 2028 and 2030 targets specifically.

How to Invest in Jagsonpal Pharmaceuticals

Start by tracking Jagsonpal Pharmaceuticals's quarterly results against the model assumptions. The Univest Screener gives you live fundamentals, analyst upgrade history, and price alerts on NSE ticker JAGSNPHARM , the same data points that drive the Jagsonpal Pharmaceuticals share price target model. Build positions in tranches across the 2027 to 2028 window rather than committing fully now, and consult a SEBI-registered financial advisor before investing.

Track This Stock Live on the Univest Screener

Conclusion

The Jagsonpal Pharmaceuticals share price target of Rs 179 for 2027, Rs 210 for 2028, and Rs 280 for 2030 reflects the analyst model built on Jagsonpal Pharmaceuticals's earnings trajectory in the pharma and healthcare sector. The near-term picture is one of consolidation; the case for patient investors is in the 2028 to 2030 window. Always verify financial data at NSE India and BSE India before making any investment decision.

Download the Univest iOS App or Univest Android App to track Jagsonpal Pharmaceuticals share price live and get daily stock recommendations.

Frequently Asked Questions on Jagsonpal Pharmaceuticals Share Price Target 2027 2028 and 2030

What is the Jagsonpal Pharmaceuticals share price target for 2027?

Ans. The Jagsonpal Pharmaceuticals share price target for 2027 is Rs 179, which is approximately 20 percent slightly below the current market price of Rs 224.31. This near-term target reflects the analyst consensus as of August 2026. Verify all data at NSE India before investing.

What is the Jagsonpal Pharmaceuticals share price target for 2030?

Ans. The 2030 analyst target for Jagsonpal Pharmaceuticals is Rs 280, implying approximately 25 percent potential upside from CMP Rs 224.31. This is the base-case extrapolation from the current earnings growth model. These are analyst estimates and not guaranteed returns.

What is the Jagsonpal Pharmaceuticals share price target for 2028?

Ans. The Jagsonpal Pharmaceuticals share price target for 2028 is Rs 210, approximately -6 percent from the current price. By FY29, the business should be past the near-term consolidation phase, which makes the 2028 target more realistically achievable than the 2027 level.

Is Jagsonpal Pharmaceuticals a good long-term investment?

Ans. Jagsonpal Pharmaceuticals has a defined earnings growth thesis in the pharma and healthcare sector, with targets that project meaningful upside by 2030. Whether it suits your portfolio depends on your risk appetite, investment horizon, and current allocation. Speak with a SEBI-registered financial advisor before deciding.

What are the key risks to the Jagsonpal Pharmaceuticals analyst forecast?

Ans. The most significant risks are regulatory risk and currency headwind. Beyond these, broader macro slowdowns and sector-specific headwinds can compress multiples even when the company itself is executing well.

What is the bull case for Jagsonpal Pharmaceuticals by 2030?

Ans. The bull case target is Rs 358 by 2030. This requires above-consensus earnings growth and a re-rating of the PE multiple , both need to happen together. These are analyst projections, not guaranteed outcomes.

What sector does Jagsonpal Pharmaceuticals belong to?

Ans. Jagsonpal Pharmaceuticals operates in the pharma and healthcare sector. This sector classification influences the peer multiples applied in the analyst target model and the macro factors that most directly affect the company's earnings outlook.

How can I track and invest in Jagsonpal Pharmaceuticals?

Ans. You can buy Jagsonpal Pharmaceuticals shares through any SEBI-registered broker using NSE ticker JAGSNPHARM. The Univest Screener lets you track live fundamentals, set price alerts, and monitor analyst ratings. Always consult a SEBI-registered financial advisor before investing.